Bristol-Myers Squibb Says NICE Recommends Daklinza for Treatment of Certain Patients with Chronic Hep C Genotypes 1, 3 and 4
October 15, 2015 at 19:37 PM EDT
Bristol-Myers Squibb (NYSE: BMY) today announced that the National Institute for Health and Care Excellence (NICE) ...
